Abstract:Diabetic peripheral neuropathy (DPN) is the prevalent type of peripheral neuropathy; it primarily impacts extremity nerves. Its multifaceted nature makes the molecular mechanisms of diabetic neuropathy intricate and incompletely elucidated. Several types of post-translational modifications (PTMs) have been implicated in the development and progression of DPN, including phosphorylation, glycation, acetylation and SUMOylation. SUMOylation involves the covalent attachment of small ubiquitin-like modifier (SUMO) proteins to target proteins, and it plays a role in various cellular processes, including protein localization, stability, and function. While the specific relationship between high blood glucose and SUMOylation is not extensively studied, recent evidence implies its involvement in the development of DPN in type 1 diabetes. In this study, we investigated the impact of SUMOylation on the onset and progression of DPN in a type 2 diabetes model using genetically modified mutant mice lacking SUMOylation, specifically in peripheral sensory neurons (SNS-Ubc9-/-). Behavioural measurement for evoked pain, morphological analyses of nerve fibre loss in the epidermis, measurement of reactive oxygen species (ROS) levels, and antioxidant molecules were analysed over several months in SUMOylation-deficient and control mice. Our longitudinal analysis at 30 weeks post-high-fat diet revealed that SNS-Ubc9-/- mice exhibited earlier and more pronounced thermal and mechanical sensation loss and accelerated intraepidermal nerve fibre loss compared to control mice. Mechanistically, these changes are associated with increased levels of ROS both in sensory neuronal soma and in peripheral axonal nerve endings in SNS-Ubc9-/- mice. In addition, we observed compromised detoxifying potential, impaired respiratory chain complexes, and reduced levels of protective lipids in sensory neurons upon deletion of SUMOylation in diabetic mice. Importantly, we also identified mitochondrial malate dehydrogenase (MDH2) as a SUMOylation target, the activity of which is negatively regulated by SUMOylation. Our results indicate that SUMOylation is an essential neuroprotective mechanism in sensory neurons in type 2 diabetes, the deletion of which causes oxidative stress and an impaired respiratory chain, resulting in energy depletion and subsequent damage to sensory neurons.

Small ubiquitin-related modifier and diabetes

Small Ubiquitin-Related Modifier and Type 1 Diabetes Mellitus

SUMO4 and type 1 diabetes

Sumoylation Modulates the Susceptibility to Type 1 Diabetes

Association Between Small Ubiquitin-Like Modifer 4 M55V Polymorphism with Type 2 Diabetes and Related Factors

SUMO conjugation contributes to immune deviation in nonobese diabetic mice by suppressing c-Maf transactivation of IL-4.

Association Between the Sumo4 M55v Polymorphism and Susceptibility to Type 2 Diabetes Mellitus: A Meta-Analysis

SUMOylation Modulates Reactive Oxygen Species (ROS) Levels and Acts as a Protective Mechanism in the Type 2 Model of Diabetic Peripheral Neuropathy

Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function

SUMOylation of Pdia3 Exacerbates Proinsulin Misfolding and ER Stress in Pancreatic Beta Cells

Association of SUMO4 Met55Val Variation with Increased Insulin Resistance in Newly Diagnosed Type 2 Diabetes in a Chinese Population

Protective effect of SERCA2a-SUMOylation by SUMO-1 on diabetes-induced atherosclerosis and aortic vascular injury

Research advance on the mechanism of abnormal small ubiquitin-like modifier in tumorigenesis and development

Protein modification by SUMO.

Post-Translational Modification of SUMOylation and Cancer: A Brief Review

The SUMO components in rheumatoid arthritis

[Sumoylation and Its Role in Hematological Disease].

SUMOylation Homeostasis in Tumorigenesis

SUMOylation of GMFB regulates its stability and function in retinal pigment epithelial cells under hyperglycemia

Insulin-dependent GLUT4 trafficking is not regulated by protein SUMOylation in L6 myocytes

The SUMO Components in Rheumatoid Arthritis.